drugset / Trial / NCT00230607

Study of the Effects of Fabrazyme Treatment on Lactation and Infants

NCT00230607

Phase 4 Terminated 7 enrolled Genzyme, a Sanofi Company
NaSingle-groupOpen-labelTreatment

Summary

The study was planned for up to 2 years (24 months). Planned full participation for both mother and infant was 24 months, planned full participation of mother and development of infant was 24 months, while planned full participation of mother and no infant participation was 6 months.

Timeline

Start
2006-05-28
Primary completion
2024-02-09
Completion
2024-02-09

Drugs

EvaluationDrugModalityDoseRoute
Subject agalsidase beta Protein / enzyme biologic Intravenous

Indications